In today’s episode, Chad sits down with Angela Stoyanovitch, a director of business development at BioAgilytix and founder of the Legal Drugs podcast. She’s a podcaster, veteran business developer, social media strategist and consultant who kicked off her career in research who has held business development roles across pre-clinical research, bioanalysis and in basic research. They discuss how she fell in love with the service side of research and her advice for others interested the drug industry.

See omnystudio.com/listener for privacy information.

In today’s episode, Chad sits down with guest scientist, Dr. Laura Sepp-Lorenzino the Chief Scientific Officer at Intellia Therapeutics. Laura is an innovative leader in drug discovery and the development of small molecules and nucleotide therapeutics. Pharma is in Laura’s blood as her mother, a pharmacist, encouraged her to pursue a career in the science. She shares how she went from studying biochemistry in Argentina and her pursuit of a Ph.D., then pivoting in a life-changing move to the United States. She also talks about the importance of paying it forward as a mentor, how gene therapy can prevent diseases, gene editing at Intellia Therapeutics, debunking stigmas behind vaccines, revisiting the Rubik’s Cube, and joining a debate club!

See omnystudio.com/listener for privacy information.

In today’s episode, Chad sits down with guest scientist, Dr. Tina Morris the executive director of the AAPS.

Tina has a distinguished career in the pharmaceutical industry including senior leadership roles at US Pharmacopia, Parenteral Drug Association, and the AAPS. 

She helps us understand the importance of these industry organizations and how we can make a difference by getting involved. She brings real credibility as a scientist in her leadership roles as we hear about her experiences as a senior-level scientist at Ciphergen and Human Genome Sciences.

They also talk about highlights of science from 2020 and beyond...talking science as scientists do. 

See omnystudio.com/listener for privacy information.

In today’s episode, Chad sits down with guest Mike Mortimer, co-founder, and partner of London-based GHO Capital.

Mike has had a distinguished career in healthcare including senior leadership roles at Quintiles, board positions with numerous healthcare companies including BioAgilitx, and for the last six years with GHO Capitals. At Quintiles he was a part of the team that grew the company to be the dominant late-stage CRO in the industry and now at GHO Capital, his team directs funding to build the future of healthcare with a focus on European investments.

They chat about the business side of the pharmaceutical industry, his thoughts on Brexit, and biking over 2,000 miles!

See omnystudio.com/listener for privacy information.

In today’s episode, Chad sits down with guest scientist Dr. Binodh DeSilva Lead, Discovery and Optimization at Bristol Myers Squibb. She has 25 years of experience within the pharmaceutical industry and has spent a significant amount of time at pharma giants, Amgen and BMS. Binodh has been highly involved in the pharmaceutical industry and more specifically in bioanalysis for much of her career.

Binodh and Chad discuss her career, how she made the leap from her home country of Sri Lanka to Kansas, and to a career on both coasts. They also talk about her industry leadership and the hobbies she has used to help fill her time during the quarantine.

See omnystudio.com/listener for privacy information.

In today’s episode, Chad sits down with guest scientist and biomarker expert, Dr. Marianne Fjording (Scientific Officer, BioAgilytix). Marianne and Chad discuss her expertise in biomarkers and EU bioanalysis- including how Denmark became a scientific hub and what fit-for-purpose really means. They also dive into Marianne’s jump from pharma to CRO, a family trip gone wrong, and how she ended up with over 100 varieties of tomatoes during the COVID quarantine.

See omnystudio.com/listener for privacy information.

Welcome to episode one of the Molecular Moments podcast!

On this first episode, Dr. Chad Briscoe is joined by his guest,  PhD scientist, Dr. Jim McNally, and they get down to business as the two explore the various nuances in the outstanding work of McNally, how his career in bioanalysis became personal in an unexpected way, and what type of gene therapy it would take to create the next Superman or Hulk!

They also discuss: 

• How bioanalysis has evolved within the gene therapy space and how it has the ability to treat patients who are suffering from cancer or diseases
• Dr. McNally’s passion and curiosity for immunogenicity 
• Unraveling immunogenetic data for drug development
• Developing drugs for gene therapy and problem-solving as a program lead 
• Whether gene therapy realistically has the potential to create superheroes 
• How Dr. McNally’s mentors, like Dr. Boris Gorovitz, while at Pfizer, helped him grow to become a better scientist. And why he thinks it’s important for him to mentor other scientists. 
• His son’s Crohn's disease diagnosis and balancing being both a father and bioanalytical scientist while seeing first-hand the benefits of biotherapies. 
• And Dr. McNally’s passion for…celery! 

Did you enjoy this episode? Be sure to subscribe and rate Molecular Moments on Apple or anywhere else you get your podcasts! 

See omnystudio.com/listener for privacy information.